Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06401421 · ClinicalTrials.gov registry record
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
A clinical trial of Breast Cancer, sponsored by Exact Sciences Corporation.
- Recruiting
- Registry status
- 1,800
- Enrollment target
- 20
- Study locations
NCT06401421: Recruiting study of Breast Cancer, sponsored by Exact Sciences Corporation.
NCT06401421 is a study of Breast Cancer that is actively recruiting participants, run by Exact Sciences Corporation. The registered enrollment target is 1,800 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06401421, a study of Breast Cancer, is actively recruiting participants, sponsored by Exact Sciences Corporation.
- RECRUITING
- Registry status
- 1,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST ctDNA MRD test
Study Locations (20)
Maryland
- Weinberg Center at Mercy - Baltimore
- Greater Baltimore Medical Center - Baltimore
- Sinai Hospital of Baltimore - Baltimore
- MedStar Georgetown Cancer Institute - Baltimore
- The Center for Cancer and Blood Disorders - Bethesda - Bethesda
Florida
- AdventHealth East Altamonte Oncology and Hematology - Altamonte Springs
- Mount Sinai Medical - Comprehensive Cancer Center - Miami Beach
- Baptist Cancer Care - Plantation - Plantation
- St. Joseph's Women's Hospital - Tampa
California
- Stanford Cancer Institute - Palo Alto
- Harbor-UCLA Medical Center - Hematology / Oncology - Torrance
- Kaiser Permanente Medical Center - Vallejo
Kentucky
- St. Elizabeth Edgewood Hospital - Edgewood
- Norton Cancer Institute - Downtown - Louisville
- Baptist Health Louisville - Louisville
Alaska
- Katmai Oncology Group - Anchorage - Anchorage
Colorado
- UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center - Aurora
Illinois
- Rush Cancer Center - Chicago
Indiana
- Deaconess Chancellor Center for Oncology - Newburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2030-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06401421
The ClinicalTrials.gov registry entry for NCT06401421 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (36% lower). The listed sponsor is Exact Sciences Corporation, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ctDNA MRD test is the first listed.
NCT06401421 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Maryland, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06401421 about?
NCT06401421 is a clinical study titled "EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)". The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
What is the current status of trial NCT06401421?
This trial is currently recruiting. The enrollment target is 1,800 participants. The study started on 2024-06-07. Estimated completion is 2030-04.
What conditions does trial NCT06401421 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06401421?
The interventions under investigation include: ctDNA MRD test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06401421?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06401421 being conducted?
This trial has 20 study locations across Alaska, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.